Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2014 (2014), Article ID 316214, 19 pages
http://dx.doi.org/10.1155/2014/316214
Research Article

Reducing TRPC1 Expression through Liposome-Mediated siRNA Delivery Markedly Attenuates Hypoxia-Induced Pulmonary Arterial Hypertension in a Murine Model

1Department of Emergency Medicine, E-Da Hospital, I-Shou University College of Medicine, Kaohsiung 82445, Taiwan
2Division of Cardiology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan
3Division of Thoracic and Cardiovascular Surgery, Department of Surgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan
4Basic Science, Nursing Department, Meiho Institute of Technology, Pingtung 91202, Taiwan
5Department of Biological Sciences, National Sun Yat-sen University, Kaohsiung 80424, Taiwan
6Center for Translational Research in Biomedical Sciences, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan
7Institute of Shock Wave Medicine and Tissue Engineering, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan

Received 7 July 2014; Revised 15 September 2014; Accepted 19 September 2014; Published 18 December 2014

Academic Editor: Gary E. Lyons

Copyright © 2014 Cheuk-Kwan Sun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Simonneau, M. A. Gatzoulis, I. Adatia et al., “Updated clinical classification of pulmonary hypertension,” Journal of the American College of Cardiology, vol. 62, no. 25, pp. D34–D41, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. N. F. Voelkel and R. M. Tuder, “Severe pulmonary hypertensive diseases: a perspective,” European Respiratory Journal, vol. 14, no. 6, pp. 1246–1250, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. S. P. Gaine and L. J. Rubin, “Primary pulmonary hypertension,” Lancet, vol. 352, no. 9129, pp. 719–725, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. G. G. Pietra, W. D. Edwards, J. M. Kay et al., “Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry,” Circulation, vol. 80, no. 5, pp. 1198–1206, 1989. View at Publisher · View at Google Scholar · View at Scopus
  5. J. R. Runo and J. E. Loyd, “Primary pulmonary hypertension,” The Lancet, vol. 361, no. 9368, pp. 1533–1544, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. G. E. D'Alonzo, R. J. Barst, S. M. Ayres et al., “Survival in patients with primary pulmonary hypertension: results from a national prospective registry,” Annals of Internal Medicine, vol. 115, no. 5, pp. 343–349, 1991. View at Publisher · View at Google Scholar · View at Scopus
  7. L. J. Rubin, “Primary pulmonary hypertension,” The New England Journal of Medicine, vol. 336, no. 2, pp. 111–117, 1997. View at Publisher · View at Google Scholar · View at Scopus
  8. I. S. Anand, B. A. K. Prasad, S. S. Chugh et al., “Effects of inhaled nitric oxide and oxygen in high-altitude pulmonary edema,” Circulation, vol. 98, no. 22, pp. 2441–2445, 1998. View at Publisher · View at Google Scholar · View at Scopus
  9. R. J. Barst, G. Maislin, and A. P. Fishman, “Vasodilator therapy for primary pulmonary hypertension in children,” Circulation, vol. 99, no. 9, pp. 1197–1028, 1999. View at Publisher · View at Google Scholar · View at Scopus
  10. L. Kalra and M. F. Bone, “Effect of nifedipine on physiologic shunting and oxygenation in chronic obstructive pulmonary disease,” The American Journal of Medicine, vol. 94, no. 4, pp. 419–423, 1993. View at Publisher · View at Google Scholar · View at Scopus
  11. D. B. Badesch, V. F. Tapson, M. D. McGoon et al., “Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial,” Annals of Internal Medicine, vol. 132, no. 6, pp. 425–434, 2000. View at Google Scholar · View at Scopus
  12. R. J. Barst, L. J. Rubin, W. A. Long et al., “A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension,” The New England Journal of Medicine, vol. 334, no. 5, pp. 296–301, 1996. View at Publisher · View at Google Scholar · View at Scopus
  13. R. N. Channick, G. Simonneau, O. Sitbon et al., “Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study,” The Lancet, vol. 358, no. 9288, pp. 1119–1123, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. L. J. Rubin, D. B. Badesch, R. J. Barst et al., “Bosentan therapy for pulmonary arterial hypertension,” The New England Journal of Medicine, vol. 346, no. 12, pp. 896–903, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Galiè, H. A. Ghofrani, A. Torbicki et al., “Sildenafil citrate therapy for pulmonary arterial hypertension,” The New England Journal of Medicine, vol. 353, no. 20, pp. 2148–2157, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. L. J. Rubin, D. B. Badesch, T. R. Fleming et al., “Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study,” Chest, vol. 140, no. 5, pp. 1274–1283, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Montell and G. M. Rubin, “Molecular characterization of the drosophila trp locus: a putative integral membrane protein required for phototransduction,” Neuron, vol. 2, no. 4, pp. 1313–1323, 1989. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Inoue, L. J. Jensen, J. Shi et al., “Transient receptor potential channels in cardiovascular function and disease,” Circulation Research, vol. 99, no. 2, pp. 119–131, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Venkatachalam and C. Montell, “TRP channels,” Annual Review of Biochemistry, vol. 76, pp. 387–417, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. Yu, I. Fantozzi, C. V. Remillard et al., “Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 38, pp. 13861–13866, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. M.-J. Lin, G. P. H. Leung, W.-M. Zhang et al., “Chronic hypoxia-induced upregulation of store-operated and receptor-operated Ca2+ channels in pulmonary arterial smooth muscle cells: a novel mechanism of hypoxic pulmonary hypertension,” Circulation Research, vol. 95, no. 5, pp. 496–505, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. G. L. Clayman, A. K. El-Naggar, S. M. Lippman et al., “Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma,” Journal of Clinical Oncology, vol. 16, no. 6, pp. 2221–2232, 1998. View at Google Scholar · View at Scopus
  23. A. Ndoye, G. Dolivet, A. Høgset et al., “Eradication of p53-mutated head and neck squamous cell carcinoma xenografts using nonviral p53 gene therapy and photochemical internalization,” Molecular Therapy, vol. 13, no. 6, pp. 1156–1162, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. C. S. Manno, G. F. Pierce, V. R. Arruda et al., “Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response,” Nature Medicine, vol. 12, no. 3, pp. 342–347, 2006. View at Google Scholar
  25. T. G. Park, J. H. Jeong, and S. W. Kim, “Current status of polymeric gene delivery systems,” Advanced Drug Delivery Reviews, vol. 58, no. 4, pp. 467–486, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. C. E. Thomas, A. Ehrhardt, and M. A. Kay, “Progress and problems with the use of viral vectors for gene therapy,” Nature Reviews Genetics, vol. 4, no. 5, pp. 346–358, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. H.-S. Zhou, D.-P. Liu, and C.-C. Liang, “Challenges and strategies: the immune responses in gene therapy,” Medicinal Research Reviews, vol. 24, no. 6, pp. 748–761, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Amarzguioui, Q. Peng, M. T. Wiiger et al., “Ex vivo and in vivo delivery of anti-tissue factor short interfering RNA inhibits mouse pulmonary metastasis of B16 melanoma cells,” Clinical Cancer Research, vol. 12, no. 13, pp. 4055–4061, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. Z. Bebök, A. M. Abai, J.-Y. Dong et al., “Efficiency of plasmid delivery and expression after lipid-mediated gene transfer to human cells in vitro,” Journal of Pharmacology and Experimental Therapeutics, vol. 279, no. 3, pp. 1462–1469, 1996. View at Google Scholar · View at Scopus
  30. S. Akhtar and I. F. Benter, “Nonviral delivery of synthetic siRNAs in vivo,” The Journal of Clinical Investigation, vol. 117, no. 12, pp. 3623–3632, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. S.-S. Kim, H. Garg, A. Joshi, and N. Manjunath, “Strategies for targeted nonviral delivery of siRNAs in vivo,” Trends in Molecular Medicine, vol. 15, no. 11, pp. 491–500, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. J. C. Gonzalez-Cobos and M. Trebak, “TRPC channels in smooth muscle cells,” Frontiers in Bioscience, vol. 15, no. 3, pp. 1023–1039, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. C.-K. Sun, F.-Y. Lee, J.-J. Sheu et al., “Early combined treatment with cilostazol and bone marrow-derived endothelial progenitor cells markedly attenuates pulmonary arterial hypertension in rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 330, no. 3, pp. 718–726, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. C.-H. Yen, S. Leu, Y.-C. Lin et al., “Sildenafil limits monocrotaline-induced pulmonary hypertension in rats through suppression of pulmonary vascular remodeling,” Journal of Cardiovascular Pharmacology, vol. 55, no. 6, pp. 574–584, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. Y.-T. Chen, T.-H. Tsai, C.-C. Yang et al., “Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction,” Journal of Translational Medicine, vol. 11, article 270, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. J.-J. Sheu, K.-C. Lin, C.-Y. Tsai et al., “Combination of cilostazol and clopidogrel attenuates Rat critical limb ischemia,” Journal of Translational Medicine, vol. 10, no. 1, article 164, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. C.-K. Sun, C.-H. Yen, Y.-C. Lin et al., “Autologous transplantation of adipose-derived mesenchymal stem cells markedly reduced acute ischemia-reperfusion lung injury in a rodent model,” Journal of Translational Medicine, vol. 9, no. 1, article 118, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Wang, L. Weigand, W. Lu, J. T. Sylvester, G. L. Semenza, and L. A. Shimoda, “Hypoxia inducible factor 1 mediates hypoxia-induced TRPC expression and elevated intracellular Ca2+ in pulmonary arterial smooth muscle cells,” Circulation Research, vol. 98, no. 12, pp. 1528–1537, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. L. Taraseviciene-Stewart, Y. Kasahara, L. Alger et al., “Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension,” The FASEB Journal, vol. 15, no. 2, pp. 427–438, 2001. View at Publisher · View at Google Scholar · View at Scopus
  40. A. I. M. Campbell, Y. Zhao, R. Sandhu, and D. J. Stewart, “Cell-based gene transfer of vascular endothelial growth factor attenuates monocrotaline-induced pulmonary hypertension,” Circulation, vol. 104, no. 18, pp. 2242–2248, 2001. View at Publisher · View at Google Scholar · View at Scopus
  41. H.-K. Yip, L.-T. Chang, C.-K. Sun et al., “Autologous transplantation of bone marrow-derived endothelial progenitor cells attenuates monocrotaline-induced pulmonary arterial hypertension in rats,” Critical Care Medicine, vol. 36, no. 3, pp. 873–880, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Izumo, A.-M. Lompré, R. Matsuoka et al., “Myosin heavy chain messenger RNA and protein isoform transitions during cardiac hypertrophy. Interaction between hemodynamic and thyroid hormone-induced signals,” The Journal of Clinical Investigation, vol. 79, no. 3, pp. 970–977, 1987. View at Publisher · View at Google Scholar · View at Scopus
  43. E. N. Olson and M. D. Schneider, “Sizing up the heart: development redux in disease,” Genes and Development, vol. 17, no. 16, pp. 1937–1956, 2003. View at Publisher · View at Google Scholar · View at Scopus